<?xml version='1.0' encoding='utf-8'?>
<document id="23785064"><sentence text="Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems."><entity charOffset="52-62" id="DDI-PubMed.23785064.s1.e0" text="fluoxetine" /></sentence><sentence text="Recent guidance on drug-drug interaction (DDI) testing recommends evaluation of circulating metabolites" /><sentence text=" However, there is little consensus on how to quantitatively predict and/or assess the risk of in vivo DDIs by multiple time-dependent inhibitors (TDIs) including metabolites from in vitro data" /><sentence text=" Fluoxetine was chosen as the model drug to evaluate the role of TDI metabolites in DDI prediction because it is a TDI of both CYP3A4 and CYP2C19 with a circulating N-dealkylated inhibitory metabolite, norfluoxetine"><entity charOffset="1-11" id="DDI-PubMed.23785064.s4.e0" text="Fluoxetine" /><entity charOffset="202-215" id="DDI-PubMed.23785064.s4.e1" text="norfluoxetine" /><pair ddi="false" e1="DDI-PubMed.23785064.s4.e0" e2="DDI-PubMed.23785064.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23785064.s4.e0" e2="DDI-PubMed.23785064.s4.e1" /></sentence><sentence text=" In pooled human liver microsomes, both enantiomers of fluoxetine and norfluoxetine were TDIs of CYP2C19, (S)-norfluoxetine was the most potent inhibitor with time-dependent inhibition affinity constant (KI) of 7 μM, and apparent maximum time-dependent inhibition rate (k(inact,app)) of 0"><entity charOffset="55-65" id="DDI-PubMed.23785064.s5.e0" text="fluoxetine" /><entity charOffset="70-83" id="DDI-PubMed.23785064.s5.e1" text="norfluoxetine" /><entity charOffset="97-104" id="DDI-PubMed.23785064.s5.e2" text="CYP2C19" /><entity charOffset="106-123" id="DDI-PubMed.23785064.s5.e3" text="(S)-norfluoxetine" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e0" e2="DDI-PubMed.23785064.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e0" e2="DDI-PubMed.23785064.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e0" e2="DDI-PubMed.23785064.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e0" e2="DDI-PubMed.23785064.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e1" e2="DDI-PubMed.23785064.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e1" e2="DDI-PubMed.23785064.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e1" e2="DDI-PubMed.23785064.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e2" e2="DDI-PubMed.23785064.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23785064.s5.e2" e2="DDI-PubMed.23785064.s5.e3" /></sentence><sentence text="059 min(-1)" /><sentence text=" Only (S)-fluoxetine and (R)-norfluoxetine were TDIs of CYP3A4, with (R)-norfluoxetine being the most potent (K(I) = 8 μM, and k(inact,app) = 0"><entity charOffset="6-20" id="DDI-PubMed.23785064.s7.e0" text="(S)-fluoxetine" /><entity charOffset="25-42" id="DDI-PubMed.23785064.s7.e1" text="(R)-norfluoxetine" /><entity charOffset="69-86" id="DDI-PubMed.23785064.s7.e2" text="(R)-norfluoxetine" /><pair ddi="false" e1="DDI-PubMed.23785064.s7.e0" e2="DDI-PubMed.23785064.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23785064.s7.e0" e2="DDI-PubMed.23785064.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23785064.s7.e0" e2="DDI-PubMed.23785064.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23785064.s7.e1" e2="DDI-PubMed.23785064.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23785064.s7.e1" e2="DDI-PubMed.23785064.s7.e2" /></sentence><sentence text="011 min(-1))" /><sentence text=" Based on in-vitro-to-in-vivo predictions, (S)-norfluoxetine plays the most important role in in vivo CYP2C19 DDIs, whereas (R)-norfluoxetine is most important in CYP3A4 DDIs"><entity charOffset="43-60" id="DDI-PubMed.23785064.s9.e0" text="(S)-norfluoxetine" /></sentence><sentence text=" Comparison of two multiple TDI prediction models demonstrated significant differences between them in in-vitro-to-in-vitro predictions but not in in-vitro-to-in-vivo predictions" /><sentence text=" Inclusion of all four inhibitors predicted an in vivo decrease in CYP2C19 (95%) and CYP3A4 (60-62%) activity" /><sentence text=" The results of this study suggest that adequate worst-case risk assessment for in vivo DDIs by multiple TDI systems can be achieved by incorporating time-dependent inhibition by both parent and metabolite via simple addition of the in vivo time-dependent inhibition rate/cytochrome P450 degradation rate constant (λ/k(deg)) values, but quantitative DDI predictions will require a more thorough understanding of TDI mechanisms" /><sentence text="" /></document>